Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Edesa Biotech, Inc.EDSA · Entity 7223 | Chief Financial Officer | May 27, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Edesa Biotech, Inc.
Report date May 27, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 129,609 |
Reported balance
After 2026-05-27 transaction · row 1
1 source rowRow 1 · 2026-05-27 · Grant · Acquired 64,609 · Balance 129,609 F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 27, 2026 Filed May 29, 2026 21:01 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 64,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-26-003802 · ownership.xml · nonDerivative · entry 1 Weiler Peter J. · CIK 0002066576 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,609 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. Read SEC document |
| May 29, 2025 Filed Jun 3, 2025 01:00 UTC | Edesa Biotech, Inc. EDSA · Entity 7223 | GrantCommon Shares | 65,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-013339 · ownership.xml · nonDerivative · entry 1 Weiler Peter J. · CIK 0002066576 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 F1 · shares: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. F1 · price: Reflects a grant of restricted share units issued pursuant to the Issuer's 2019 Equity Incentive Compensation Plan, which shall vest monthly in equal proportions over thirty-six (36) months, commencing on the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.